Astellas Pharma Inc. - Research and Development

Astellas Pharma Inc.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.

The item "Research-and-Development" stands at 298.61 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 06/30/2024.

Astellas Pharma Inc.'s second quarter result of 71.59 Billion JPY for the item "Research and Development" represents a decrease of -0.15 percent compared to it's first quarter result.

Also, Astellas Pharma Inc.'s second quarter result of 71.59 Billion JPY for the item "Research and Development" represents a decrease of -16.28 percent compared to it's second quarter result of last year.

Looking again at the trailing twelve months series (TTM), Astellas Pharma Inc.'s second quarter result of 298.61 Billion JPY for the item "Research and Development" represents a decrease of -4.45 percent compared to it's first quarter result.


Regarding the One-Year-Change of the series, the current value constitutes a decrease of -8.00 percent compared to the value the year prior.
The 1 year change in percent is -8.00.
The 3 year change in percent is 12.21.
The 5 year change in percent is 29.30.
The 10 year change in percent is 34.75.

The Serie's long term average value is 230.32 Billion Japanese Yens. It's latest available value, on 09/30/2025, is 29.65 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 03/31/2013, to it's latest available value, on 09/30/2025, is +523.99%.
The Serie's change in percent from it's maximum value, on 12/31/2014, to it's latest available value, on 09/30/2025, is -12.04%.